Re lipopolysaccharide

monomeric Re from E coli is more active than the aggregated form in the Limulus amebocyte lysate assay & in inducing Egr-1 mRna in murine peritoneal macrophages; amino acid sequence has been determined

Also Known As:

Networked: 9 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bowles, P: 1 article (11/2010)
2.	Entrican, G: 1 article (11/2010)
3.	Fitch, P M: 1 article (11/2010)
4.	Howie, S E M: 1 article (11/2010)
5.	Longbottom, D: 1 article (11/2010)
6.	Paterson, M: 1 article (11/2010)
7.	Wheelhouse, N M: 1 article (11/2010)

Related Diseases

1.	Hemolysis 12/15/1989 - "Binding characteristics of these three mAb were investigated against Ag (ReLPS, lipid A, derivatives of lipid A) in solid phase (ELISA) and in fluid phase (C consumption, inhibition studies), and upon incorporation in membranes (E: passive hemolysis assay, and liposomes: inhibition studies). " 07/01/1977 - "Re lipopolysaccharide and lipid A were found to possess distinct antigenic determinants as measured by hemagglutination, hemolysis, and precipitin techniques. "
2.	Infections 11/01/2010 - "In vitro, lung epithelial cells up-regulated MIP-2/CXCL2 in response to both rough lipopolysaccharide (reLPS) and Cp infection. " 10/01/1991 - "In Gram-negative infections, ACA were inhibited by ReLPS more effectively than by cardiolipin. " 11/20/1986 - "Furthermore results obtained by the ELISA-ReLPS on 55 sera from patients with clinical evidence of Chlamydiae infection correlated well with the values obtained by an ELISA using Chlamydia-coated microtitration plates and by two immunofluorescence tests using Chlamydia trachomatis and Chlamydia psittaci as antigens. " 10/01/1993 - "A complement fixation (CF) test, a micro-immunofluorescence (micro-IF) test and an enzyme immunoassay (EIA) using Re-lipopolysaccharide as antigen were compared in the diagnosis of chlamydial infection in 136 mainly elderly patients hospitalized with community-acquired pneumonia during a Chlamydia pneumoniae epidemic in Finland in 1986-1987. "
3.	Necrosis 12/01/1994 - "Stimulation of PMN with tumour necrosis factor (TNF) or LPS enhanced the binding of FITC-ReLPS at 4 degrees. " 09/01/1994 - "Pentaacyl diphosphoryl lipid A derived from the nontoxic lipopolysaccharide (LPS) of Rhodobacter sphaeroides ATCC 17023 (RsDPLA) did not induce tumour necrosis factor-alpha nor interleukin-6 release in the murine macrophage-like cell line J774.1. However, it effectively inhibited the induction of these two cytokines by LPS of Salmonella minnesota Re mutant R595 (ReLPS) in a concentration-dependent manner. "
4.	Sarcoidosis (Schaumann Disease) 11/01/1996 - "By enzyme immunoassay, 20 sarcoidosis patients had antibody against ReLPS but that cross-reacts with chlamydial LPS. "
5.	Pneumonia (Pneumonitis) 10/01/1993 - "A complement fixation (CF) test, a micro-immunofluorescence (micro-IF) test and an enzyme immunoassay (EIA) using Re-lipopolysaccharide as antigen were compared in the diagnosis of chlamydial infection in 136 mainly elderly patients hospitalized with community-acquired pneumonia during a Chlamydia pneumoniae epidemic in Finland in 1986-1987. "

Related Drugs and Biologics

1.	Lipid A
2.	Liposomes (Liposome)
3.	Lipopolysaccharides
4.	Enzymes
5.	Antigens
6.	Fluorescein-5-isothiocyanate (FITC)
7.	Cytokines
8.	Interleukin-6 (Interleukin 6)
9.	Complement System Proteins (Complement)
10.	Cardiolipins (Cardiolipin)